Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 4:28 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1513–1536 of 2,913 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Event Clear all

Conditions: Healthy
Interventions: Secondhand cannabis emissions/smoke exposure; Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 21 Years to 50 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Obesity, Airway Complication of Anesthesia, Intubation; Difficult or Failed
Interventions: endotracheal intubation; Procedure
Lead sponsor: Zeliha Alicikus; Government
Eligibility: 18 Years and older
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Posttraumatic Stress Disorder
Interventions: Expressive Writing, Control Writing; Behavioral
Lead sponsor: Minneapolis Veterans Affairs Medical Center; Federal
Eligibility: 19 Years and older
Enrollment: 1,292 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Venous Thrombosis
Interventions: PD 0348292, Enoxaparin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 1,225 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 58
States / cities: Birmingham, Alabama • Little Rock, Arkansas • North Little Rock, Arkansas + 29 more

Conditions: Metastatic Prostate Cancer
Interventions: Atezolizumab, Abiraterone, Prednisone, GnRH analog, Stereotactic Body Radiotherapy (SBRT), Enzalutamide, Follow up; Drug · Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: End Stage Renal Disease
Interventions: REVEAL Insertable Cardiac Monitor (ICM); Device
Lead sponsor: Medtronic Corporate Technologies and New Ventures; Industry
Eligibility: 21 Years and older
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Augusta, Georgia • Boston, Massachusetts • Cincinnati, Ohio + 2 more

Conditions: Heart Transplant
Interventions: Evolocumab; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years to 80 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Post-Traumatic Stress Disorders, Stress Disorders, Combat Disorders
Interventions: Cognitive Behavioral Therapy; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 3
States / cities: San Antonio, Texas

Conditions: Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
Interventions: Asundexian (BAY2433334), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 12,327 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 108
States / cities: Fairhope, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 87 more

Conditions: Encephalopathy, Radiation Effect
Interventions: Gocovri (extended-release amantidine); Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: New York, New York

Conditions: Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Interventions: Not listed
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: 18 Years and older
Enrollment: 697 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • San Jose, California • Stanford, California + 18 more

Conditions: no Condition, Electroencephalography, Pupil Diameter
Interventions: Transdermal Vagus Nerve Stimulation (tVNS); Device
Lead sponsor: Arkansas Tech University; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Russellville, Arkansas

Conditions: Hypertension
Interventions: SERVE OC Intervention, Enhanced Standard Intervention; Behavioral
Lead sponsor: University of California, Irvine; Other
Eligibility: 5 Years and older
Enrollment: 483 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Irvine, California

Conditions: Anxiety
Interventions: Low-intensity focused ultrasound, Low-intensity focused ultrasound - sham; Device
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Roanoke, Virginia

Conditions: Metastatic Colorectal Cancer, Colorectal Cancer Metastatic, Carcinoma
Interventions: Sym004, Futuximab, Modotuximab; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Duarte, California • Atlanta, Georgia • Boston, Massachusetts + 2 more

Conditions: Stress Disorders, Post-Traumatic, Smoking
Interventions: Cognitive Processing Therapy (CPT), Bupropion, nicotine replacement therapy (NRT), Integrated Care for Smoking Cessation (ICSC), smokefreeVET; Behavioral · Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Reperfusion Injury, STEMI
Interventions: Bendavia (MTP-131), Placebo; Drug
Lead sponsor: Stealth BioTherapeutics Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 3
States / cities: Port Orange, Florida • Detroit, Michigan • Omaha, Nebraska

Conditions: Metastatic Cancer
Interventions: Metastatic Cancer; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pneumonia, Bacterial
Interventions: procalcitonin; Diagnostic Test
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 110 Years
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 6
States / cities: Torrington, Connecticut • Atlanta, Georgia • Boston, Massachusetts + 3 more

Conditions: Endometrial Neoplasms
Interventions: pembrolizumab, carboplatin, paclitaxel, docetaxel, cisplatin; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 35
States / cities: Phoenix, Arizona • La Jolla, California • Riverside, California + 28 more

Conditions: Breast Cancer
Interventions: Poziotinib; Drug
Lead sponsor: Spectrum Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 35
States / cities: Huntsville, Alabama • Anaheim, California • Greenbrae, California + 31 more

Conditions: Hepatitis C
Interventions: LADR Treatment; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 8
States / cities: Los Angeles, California • San Francisco, California • Denver, Colorado + 5 more

Conditions: Non-Segmental Vitiligo
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Irvine, California • Redwood City, California • Boca Raton, Florida + 16 more

Conditions: Emotions, Rumination
Interventions: Social regulation, Self regulation; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Measuring Environmental Tobacco and Cannabis: Pollutants and Exposures

Peri-Intubation Adverse Airway Events in Critically Ill Patients With Morbid and Super Obesity

Military to Civilian: Trial of an Intervention to Promote Postdeployment Reintegration

Evaluation of PD 0348292 for Preventing Blood Clots in the Lungs or Deep Leg Veins of Patients After Knee Surgery

Study of Abiraterone Acetate or Enzalutamide, Atezolizumab, GnRH Analog and Radiation Therapy in Men With Newly Diagnosed Hormone-sensitive Prostate Cancer

Monitoring in Dialysis -- a Prospective, Multi-center, Single-arm, Non-randomized, Observational Study in Patients Who Are Undergoing Hemodialysis.

Impact of Evolocumab in Cardiac Transplant Patients With CAV

Psychotherapy Treatment of Deployment-Related PTSD in Primary Care Settings

A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

Use of Gocovri to Improve Disability Due to Radiation Encephalopathy

PROSPECT: An Imaging Study in Patients With Unstable Atherosclerotic Lesions

Testing the Noradrenergic Hypothesis of Transcutaneous Vagus Nerve Stimulation

Skills-Based Educational Strategies for Reduction of Vascular Events in Orange County

LIFU for Anxiety Management

Sym004 Versus Futuximab or Modotuximab in Patients With mCRC

CPT and Smoking Cessation

Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary Events

A Study of the ApricityCare Program for Early Detection and Management of Treatment-Related Adverse Events in Patients With Cancer

PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)

Study of Poziotinib in Participants With HER2-Positive Metastatic Breast Cancer

Pre-Transplant Treatment to Prevent Recurrence of Hepatitis C After Liver Transplantation

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

Neural Predictors of Social Emotion Regulation Training